New combo therapy aims to knock out high-risk prostate cancer
Disease control
Recruiting now
This study is for men with high-risk prostate cancer that hasn't spread. It tests whether adding an immunotherapy drug (pembrolizumab) and a targeted drug (olaparib) to standard radiation therapy can better control the cancer. About 64 participants will receive the combination an…
Phase: PHASE2 • Sponsor: Zin W Myint • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC